Trade Citius Pharmaceuticals, Inc. - CTXR CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
| Spread | 0.0074 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Citius Pharmaceuticals Inc ESG Risk Ratings
High Medium Low Negligible
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Key Stats
| Prev. Close* | 0.6895 |
| Open* | 0.6677 |
| 1-Year Change* | -44.36% |
| Day's Range* | 0.6616 - 0.6907 |
| 52 wk Range | 0.77-1.71 |
| Average Volume (10 days) | 549.08K |
| Average Volume (3 months) | 30.52M |
| Market Cap | 139.05M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 158.86M |
| Revenue | N/A |
| EPS | -0.21 |
| Dividend (Yield %) | N/A |
| Beta | 1.40 |
| Next Earnings Date | Dec 20, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 29, 2023 | 0.6850 | 0.0173 | 2.59% | 0.6677 | 0.6912 | 0.6577 |
| Sep 28, 2023 | 0.6895 | 0.0218 | 3.26% | 0.6677 | 0.6926 | 0.6632 |
| Sep 27, 2023 | 0.6891 | 0.0405 | 6.24% | 0.6486 | 0.7076 | 0.6486 |
| Sep 26, 2023 | 0.6486 | -0.0100 | -1.52% | 0.6586 | 0.6836 | 0.6266 |
| Sep 25, 2023 | 0.6618 | -0.0358 | -5.13% | 0.6976 | 0.7014 | 0.6575 |
| Sep 22, 2023 | 0.6954 | 0.0073 | 1.06% | 0.6881 | 0.7043 | 0.6881 |
| Sep 21, 2023 | 0.6885 | -0.0091 | -1.30% | 0.6976 | 0.7049 | 0.6878 |
| Sep 20, 2023 | 0.6916 | -0.0260 | -3.62% | 0.7176 | 0.7326 | 0.6876 |
| Sep 19, 2023 | 0.7149 | -0.0127 | -1.75% | 0.7276 | 0.7344 | 0.7076 |
| Sep 18, 2023 | 0.7331 | -0.0245 | -3.23% | 0.7576 | 0.7746 | 0.7226 |
| Sep 15, 2023 | 0.7714 | 0.0138 | 1.82% | 0.7576 | 0.7866 | 0.7476 |
| Sep 14, 2023 | 0.7557 | 0.0180 | 2.44% | 0.7377 | 0.7676 | 0.7276 |
| Sep 13, 2023 | 0.7277 | -0.0549 | -7.02% | 0.7826 | 0.7826 | 0.7176 |
| Sep 12, 2023 | 0.7782 | -0.0394 | -4.82% | 0.8176 | 0.8176 | 0.7775 |
| Sep 11, 2023 | 0.7945 | -0.1130 | -12.45% | 0.9075 | 0.9276 | 0.7725 |
| Sep 8, 2023 | 0.8818 | -0.0228 | -2.52% | 0.9046 | 0.9266 | 0.8766 |
| Sep 7, 2023 | 0.8719 | -0.0147 | -1.66% | 0.8866 | 0.8866 | 0.8566 |
| Sep 6, 2023 | 0.8534 | -0.0537 | -5.92% | 0.9071 | 0.9151 | 0.8466 |
| Sep 5, 2023 | 0.9010 | -0.0203 | -2.20% | 0.9213 | 0.9281 | 0.8965 |
| Sep 1, 2023 | 0.9277 | 0.0289 | 3.22% | 0.8988 | 0.9339 | 0.8988 |
Citius Pharmaceuticals, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Wednesday, December 20, 2023 | ||
| Time (UTC) 10:59 | Country US
| Event Q4 2023 Citius Pharmaceuticals Inc Earnings Release Q4 2023 Citius Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
| Wednesday, February 7, 2024 | ||
| Time (UTC) 13:00 | Country US
| Event Citius Pharmaceuticals Inc Annual Shareholders Meeting Citius Pharmaceuticals Inc Annual Shareholders MeetingForecast -Previous - |
| Thursday, February 8, 2024 | ||
| Time (UTC) 10:59 | Country US
| Event Q1 2024 Citius Pharmaceuticals Inc Earnings Release Q1 2024 Citius Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 33.3161 | 23.3653 | 17.7107 | 15.5984 | 13.3391 |
| Selling/General/Admin. Expenses, Total | 15.6606 | 11.2914 | 8.89788 | 7.00146 | 7.22622 |
| Research & Development | 17.6555 | 12.2405 | 8.81281 | 8.5969 | 6.56293 |
| Operating Income | -33.3161 | -23.3653 | -17.7107 | -15.5984 | -13.3391 |
| Interest Income (Expense), Net Non-Operating | 0.2514 | 0.25099 | 0.0524 | 0.03622 | -0.01584 |
| Net Income Before Taxes | -33.0647 | -23.0544 | -17.5481 | -15.5621 | -12.5366 |
| Net Income After Taxes | -33.6407 | -23.0544 | -17.5481 | -15.5621 | -12.5366 |
| Net Income Before Extra. Items | -33.6407 | -23.0544 | -17.5481 | -15.5621 | -12.5366 |
| Net Income | -33.6407 | -23.0544 | -17.5481 | -15.5621 | -12.5366 |
| Income Available to Common Excl. Extra. Items | -33.6407 | -24.5053 | -17.5481 | -15.5621 | -12.5366 |
| Income Available to Common Incl. Extra. Items | -33.6407 | -24.5053 | -17.5481 | -15.5621 | -12.5366 |
| Diluted Net Income | -33.6407 | -24.5053 | -17.5481 | -15.5621 | -12.5366 |
| Diluted Weighted Average Shares | 146.082 | 108.599 | 39.1652 | 20.1618 | 10.7319 |
| Diluted EPS Excluding Extraordinary Items | -0.23029 | -0.22565 | -0.44805 | -0.77186 | -1.16817 |
| Diluted Normalized EPS | -0.23029 | -0.22718 | -0.44805 | -0.77186 | -1.2101 |
| Unusual Expense (Income) | 0 | -0.16656 | 0 | -0.45 | |
| Other, Net | 0 | 0.05992 | 0.11021 | 0 | 0.81834 |
| Total Adjustments to Net Income | 0 | -1.45088 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 8.67211 | 10.6853 | 3.66419 | 7.54957 | 8.91665 |
| Selling/General/Admin. Expenses, Total | 4.90744 | 5.95845 | 3.80437 | 3.69234 | 4.02846 |
| Research & Development | 3.76468 | 4.72686 | 3.44552 | 3.85723 | 4.88819 |
| Operating Income | -8.67211 | -10.6853 | -3.66419 | -7.54957 | -8.91665 |
| Interest Income (Expense), Net Non-Operating | 0.33678 | 0.30328 | 0.21455 | 0.13483 | 0.05302 |
| Other, Net | 0 | 0 | |||
| Net Income Before Taxes | -8.33533 | -10.382 | -3.44965 | -7.41474 | -8.86363 |
| Net Income After Taxes | -8.47933 | -10.526 | -3.59365 | -7.99074 | -8.86363 |
| Net Income Before Extra. Items | -8.47933 | -10.526 | -3.59365 | -7.99074 | -8.86363 |
| Net Income | -8.47933 | -10.526 | -3.59365 | -7.99074 | -8.86363 |
| Income Available to Common Excl. Extra. Items | -8.47933 | -10.526 | -3.59365 | -7.99074 | -8.86363 |
| Income Available to Common Incl. Extra. Items | -8.47933 | -10.526 | -3.59365 | -7.99074 | -8.86363 |
| Diluted Net Income | -8.47933 | -10.526 | -3.59365 | -7.99074 | -8.86363 |
| Diluted Weighted Average Shares | 153.775 | 146.252 | 146.211 | 146.146 | 146.13 |
| Diluted EPS Excluding Extraordinary Items | -0.05514 | -0.07197 | -0.02458 | -0.05468 | -0.06066 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.05514 | -0.07197 | -0.04052 | -0.05468 | -0.06066 |
| Total Adjustments to Net Income | 0 | 0 | |||
| Unusual Expense (Income) | 0 | 0 | -3.58569 | 0 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 44.5643 | 72.8143 | 13.982 | 7.94192 | 10.0601 |
| Cash and Short Term Investments | 41.7117 | 70.073 | 13.8597 | 7.8938 | 9.184 |
| Cash & Equivalents | 41.7117 | 70.073 | 13.8597 | 7.8938 | 9.184 |
| Prepaid Expenses | 2.85258 | 2.7414 | 0.12224 | 0.04811 | 0.05773 |
| Total Assets | 113.999 | 142.429 | 43.7737 | 36.7464 | 31.0505 |
| Property/Plant/Equipment, Total - Net | 0.65017 | 0.82985 | 0.98778 | 0.00059 | 0.00148 |
| Property/Plant/Equipment, Total - Gross | |||||
| Accumulated Depreciation, Total | |||||
| Goodwill, Net | 9.3468 | 9.3468 | 9.3468 | 9.3468 | 1.5868 |
| Intangibles, Net | 59.4 | 59.4 | 19.4 | 19.4 | 19.4 |
| Other Long Term Assets, Total | 0.03806 | 0.03806 | 0.05709 | 0.05709 | 0.00217 |
| Total Current Liabilities | 4.53001 | 3.98229 | 4.09713 | 4.60772 | 3.18484 |
| Accounts Payable | 1.16538 | 1.2771 | 1.85624 | 2.71354 | 1.57344 |
| Accrued Expenses | 3.36463 | 2.7052 | 2.06793 | 1.72121 | 1.43843 |
| Notes Payable/Short Term Debt | 0 | 0 | 0.17297 | 0.17297 | 0.17297 |
| Other Current Liabilities, Total | 0 | ||||
| Total Liabilities | 11.1734 | 10.2467 | 10.103 | 9.59352 | 3.18484 |
| Total Long Term Debt | 0 | 0 | 0.16458 | 0 | 0 |
| Total Equity | 102.826 | 132.182 | 33.6707 | 27.1529 | 27.8657 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | ||
| Common Stock | 0.14621 | 0.14598 | 0.05558 | 0.02893 | 0.0162 |
| Additional Paid-In Capital | 232.368 | 228.084 | 104.209 | 80.1697 | 68.1073 |
| Retained Earnings (Accumulated Deficit) | -129.688 | -96.0478 | -70.5939 | -53.0458 | -40.2578 |
| Total Liabilities & Shareholders’ Equity | 113.999 | 142.429 | 43.7737 | 36.7464 | 31.0505 |
| Total Common Shares Outstanding | 146.211 | 145.979 | 55.577 | 28.9305 | 16.1988 |
| Total Receivables, Net | 0.81834 | ||||
| Long Term Debt | 0 | 0.16458 | 0 | ||
| Deferred Income Tax | 5.5618 | 4.9858 | 4.9858 | 4.9858 | |
| Other Liabilities, Total | 0.48125 | 0.67823 | 0.85547 | ||
| Minority Interest | 0.60038 | 0.60038 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 34.9011 | 42.3174 | 44.5643 | 50.8345 | 58.2593 |
| Cash and Short Term Investments | 29.0655 | 36.8872 | 41.7117 | 48.0442 | 55.7562 |
| Cash & Equivalents | 29.0655 | 36.8872 | 41.7117 | 48.0442 | 55.7562 |
| Prepaid Expenses | 5.8356 | 5.43013 | 2.85258 | 2.79032 | 2.50311 |
| Total Assets | 104.241 | 111.705 | 113.999 | 120.316 | 127.786 |
| Property/Plant/Equipment, Total - Net | 0.55484 | 0.60299 | 0.65017 | 0.69642 | 0.74177 |
| Goodwill, Net | 9.3468 | 9.3468 | 9.3468 | 9.3468 | 9.3468 |
| Intangibles, Net | 59.4 | 59.4 | 59.4 | 59.4 | 59.4 |
| Other Long Term Assets, Total | 0.03806 | 0.03806 | 0.03806 | 0.03806 | 0.03806 |
| Total Current Liabilities | 6.20968 | 4.53717 | 4.53001 | 4.46112 | 4.02192 |
| Accounts Payable | 2.72559 | 1.53758 | 1.16538 | 1.69052 | 1.70513 |
| Accrued Expenses | 3.48408 | 2.99959 | 3.36463 | 2.7706 | 2.3168 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 13.0347 | 11.2719 | 11.1734 | 10.5802 | 10.1904 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Long Term Debt | |||||
| Deferred Income Tax | 5.8498 | 5.7058 | 5.5618 | 4.9858 | 4.9858 |
| Minority Interest | 0.60038 | 0.60038 | 0.60038 | 0.60038 | 0.60038 |
| Other Liabilities, Total | 0.37483 | 0.42857 | 0.48125 | 0.53288 | 0.5823 |
| Total Equity | 91.2061 | 100.433 | 102.826 | 109.736 | 117.596 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
| Common Stock | 0.14636 | 0.14621 | 0.14621 | 0.14613 | 0.14613 |
| Additional Paid-In Capital | 234.868 | 233.569 | 232.368 | 231.287 | 230.284 |
| Retained Earnings (Accumulated Deficit) | -143.808 | -133.282 | -129.688 | -121.698 | -112.834 |
| Total Liabilities & Shareholders’ Equity | 104.241 | 111.705 | 113.999 | 120.316 | 127.786 |
| Total Common Shares Outstanding | 146.358 | 146.211 | 146.211 | 146.13 | 146.13 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -33.6407 | -23.0544 | -17.5481 | -15.5621 | -12.5366 |
| Cash From Operating Activities | -28.3613 | -24.2504 | -16.9307 | -12.4377 | -11.3181 |
| Cash From Operating Activities | 0.00292 | 0.00149 | 0.00084 | 0.00089 | 0.00175 |
| Non-Cash Items | 4.46091 | 1.5198 | 1.48355 | 0.92758 | 0.7069 |
| Cash Taxes Paid | |||||
| Cash Interest Paid | 0 | 0.00019 | |||
| Changes in Working Capital | 0.23956 | -2.71727 | -0.86697 | 2.19592 | 0.50985 |
| Cash From Investing Activities | 0 | -40.0069 | -0.00183 | 0 | 0 |
| Other Investing Cash Flow Items, Total | 0 | ||||
| Cash From Financing Activities | 0 | 120.471 | 22.8984 | 11.1475 | 17.298 |
| Financing Cash Flow Items | 0 | 18.4504 | 0 | 0 | |
| Issuance (Retirement) of Debt, Net | 0 | -0.17297 | 0.16458 | 0 | 0 |
| Net Change in Cash | -28.3613 | 56.2132 | 5.96594 | -1.2902 | 5.9799 |
| Capital Expenditures | 0 | -40.0069 | -0.00183 | 0 | 0 |
| Issuance (Retirement) of Stock, Net | 0 | 102.193 | 22.7339 | 11.1475 | 17.298 |
| Deferred Taxes | 0.576 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -14.1197 | -3.59365 | -33.6407 | -25.6499 | -16.7863 |
| Cash From Operating Activities | -12.6774 | -4.82444 | -28.3613 | -22.0287 | -14.3167 |
| Cash From Operating Activities | 0.00146 | 0.00073 | 0.00292 | 0.00219 | 0.00146 |
| Non-Cash Items | 2.56255 | 1.24754 | 4.46091 | 3.3344 | 2.28611 |
| Changes in Working Capital | -1.40977 | -2.62306 | 0.23956 | 0.28456 | 0.18199 |
| Cash From Financing Activities | 0.03127 | 0 | 0 | 0 | 0 |
| Financing Cash Flow Items | 0 | 0 | 0 | 0 | |
| Issuance (Retirement) of Stock, Net | 0.03127 | 0 | 0 | 0 | |
| Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | ||
| Net Change in Cash | -12.6462 | -4.82444 | -28.3613 | -22.0287 | -14.3167 |
| Cash From Investing Activities | 0 | 0 | 0 | ||
| Capital Expenditures | 0 | 0 | |||
| Deferred Taxes | 0.288 | 0.144 | 0.576 | ||
| Other Investing Cash Flow Items, Total | 0 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
Leverage
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Citius Pharmaceuticals, Inc. Company profile
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution for treating patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering with hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, a engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.| Industry: | Biotechnology & Medical Research (NEC) |
11 Commerce Dr Fl 1
CRANFORD
NEW JERSEY 07016-3501
US
Income Statement
- Annual
- Quarterly
News
How to Trade The Triple Top
Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.
14:13, 27 September 2023
Q4 lookahead: US indices starting to show signs of trouble?
US indices start to draw attention as traders focus on the outlook for Q4.
07:20, 27 September 2023
USD/JPY Climbs Towards Key Highs
USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.
11:32, 26 September 2023
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com